Omega Funds — Full Portfolio
20 tracked investments · listed companies and verified rows first
Beta Bionics develops the iLet Bionic Pancreas System, an insulin delivery device for people with type 1 diabetes aged 6 and older that requires a physician's prescription.
Digital HealthHealthtechMedical DevicesIrvine, US
Edward Damiano(Executive Officer, Director)Gilbert Clarke(Executive Officer)Edward Raskin(Executive Officer, Director)Mike Roskino(Executive Officer)Agustin Mohedas(Director)Jeff Hitchcock(Director)
Board seatFrancesco Draetta· per SEC Form D · $101.8M raise · filed Sep 2023
Biotechnology company developing orally available therapies for chronic inflammatory and autoimmune diseases.
BiotechNew York, US
Andreas Muehler(Executive Officer)inDaniel Vitt(Executive Officer, Director)inJASON TARDIO(Executive Officer)GLENN WHALEY(Executive Officer)INDERPAL SINGH(Executive Officer)Patrick Walsh(Executive Officer)
Board seatVincent Ossipow· per SEC Form D · $60M raise · filed Oct 2022
Co-investorsBayern Kapitalbmp VenturesFund+Pontifax Venture Capital
Nuvation Bio is a global oncology company developing and commercializing novel therapies for difficult-to-treat cancers, targeting indications where conventional treatments have failed.
BiotechHealthtechNew York, US
David Hung(Founder, President & Chief Executive Officer)
Board seatMichelle DoigClaudio Nessi· per SEC Form D · $275.3M raise · filed Oct 2020
Co-investorsAisling CapitalDecheng CapitalEcoR1 CapitalVertex Ventures China
BiotechBoston, US
Mary DiBiase(Executive Officer)Christophe Arbet-Engels(Executive Officer)David Kirske(Executive Officer)John Volpone(Executive Officer)Mark Baldry(Executive Officer)Adam Craig(Executive Officer, Director)
Board seatClaudio Nessi· per SEC Form D · $50.5M raise · filed May 2017
Co-investorsPolaris Partners
Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Adam Friedman(Chief Executive Officer)inAndrew Fedder(Executive Officer, Director)inBrian Piper(Executive Officer, Director)
Co-investorsAtlas VentureLightspeed Venture PartnersVida VenturesTenmileAbingworthBiotechnology Value Fund
Callio Therapeutics develops next-generation dual-payload antibody-drug conjugates (ADCs) with differentiated payload and linker technologies for targeted cancer treatment.
BiotechMedical DevicesSeattle, US
Piers Ingram(President, Co-Founder)Jerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)Zachary Hornby(Chief Executive Officer)
Co-investorsNovo HoldingsFrazier Life SciencesJeito CapitalNorwest Venture Partners
Alveus Therapeutics develops next-generation metabolic and obesity therapies, including its lead asset ALV-100 (in Phase 2) and a preclinical amylin pipeline of peptides, oral small molecules, and novel formats aimed at sustainable weight loss with better tolerability.
BiotechHealthtechLongevityPhiladelphia, US
Raj Kannan(Executive Officer, Director)
BoardIvan Gergel(Director)inJan Van de Bossche(Director)inGarrett Ingram(Director)Gregory Parekh(Director)
Board seatClaudio Nessi· per SEC Form D · $110.7M raise · filed Jan 2026
Co-investorsAndera PartnersAvego BioScience CapitalGlobal BioAccess FundJeito CapitalNew Rhein Healthcare Investors, LLCSeroba Life Sciences+2 more
South San Francisco, US
Board seatOtello Stampacchia· per SEC Form D · $117M raise · filed Mar 2021
Co-investorsFrazier Life Sciences
BiotechCambridge, US
Praveen Tipirneni(Executive Officer, Director)
BoardAaron Royston(Director)Michael Gladstone(Director)inXiaodi Su(Director)
Board seatMichelle Doig· per SEC Form D · $37.5M raise · filed Jan 2026
Co-investorsAtlas VentureBain Capital Life SciencesJanus Henderson InvestorsLAVvenBio Global StrategicvenBio Partners+1 more
BiotechVancouver
Frank Perabo(Executive Officer)Franklin Berger(Director)Raymond Andersen(Executive Officer, Director)Scott Requadt(Director)Paul Cossum(Executive Officer)David Wood(Executive Officer)
Board seatOtello Stampacchia· per SEC Form D · $36M raise · filed Aug 2019
Co-investorsClarus
BiotechBoston, US
Jotin Marango(Executive Officer)Mark Manfredi(Executive Officer, Director)Jeffrey Ecsedy(Executive Officer)Sergio Santillana(Executive Officer)Michelle Zhang(Executive Officer)
Board seatOtello Stampacchia· per SEC Form D · $75M raise · filed Jul 2025
Co-investorsAtlas VentureBiotechnology Value FundForesite CapitalOrbiMedRTW Investments L.P.
BiotechWaltham, US
Timothy Springer(Director)Praveen Tiprirneni(Executive Officer, Director)Robert Farrell(Executive Officer)
BoardBarbara Dalton(Director)Ramy Farid(Director)Kevin Bitterman(Director)in
Board seatOtello Stampacchia· per SEC Form D · $80M raise · filed Oct 2018
Co-investorsAtlas VenturePolaris Partners
BiotechBoston, US
Adam Friedman(Executive Officer, Director)inGary Glick(Executive Officer, Director)inAndrew Fedder(Executive Officer)Darrin Stuart(Executive Officer)Erica Jackson(Executive Officer)Amanda Valentino(Executive Officer)
Board seatOtello Stampacchia· per SEC Form D · $150M raise · filed Jul 2024
Co-investorsAtlas VentureAvoro Capital AdvisorsEcoR1 CapitalFrazier Life SciencesNextech InvestVida Ventures+2 more
Spiro Medical develops an implantable neuromodulation system using targeted spinal nerve stimulation to modulate respiratory function in patients with severe, uncontrolled asthma who have not responded to conventional treatments.
BiotechHealthtechMedical DevicesBelleair Bluffs, US
Rinda Sama(Executive Officer)
BoardBrian Mooney(Director)
Board seatClaudio Nessi· per SEC Form D · $69.1M raise · filed Jan 2026
Co-investorsAndera PartnersSupernova Invest
BiotechPalo Alto, US
Idan Elmelech(Executive Officer)Pedro Beltran(Executive Officer)Frank McCormick(Director)Neil Kumar(Director)Eli Wallace(Executive Officer)Raymond Kelleher(Director)
Board seatMichelle Doig· per SEC Form D · $200M raise · filed May 2024
Third Arc Bio develops breakthrough treatments in oncology and immunology through advanced biologics engineering.
BiotechMedical DevicesLower Gwynedd, US
Joseph Erhardt(Executive Officer)Peter Lebowitz(Executive Officer, Director)
BoardArjun Goyal(Director)in
Board seatFrancesco DraettaOtello Stampacchia· per SEC Form D
Co-investorsAndreessen HorowitzVida Venturesabrdn plcBiotechnology Value FundForesite CapitalHillhouse Investment+1 more
XII Medical develops neuromodulation therapies for treating obstructive sleep apnea, focusing on simplifying treatment options and improving patient outcomes.
Deep TechDigital HealthHealthtechMedical DevicesUnion City, US
Garrett Schwab(Chief Executive Officer)Shane Kreidel(Secretary and Chief Financial Officer)inZachary Eisen(Director)
BoardDuke Rohlen(Director)inJD Friedland(Director)
Board seatSaoussen Ben Halima· per SEC Form D
Co-investorsAPERTURE Venture PartnersBroadview VenturesCincyTechIntuitive VenturesJobsOhio VenturesAjax Health
GelSight develops high-resolution tactile imaging and surface metrology technology for measuring and analyzing surface properties in manufacturing.
Advanced ManufacturingAI & Machine LearningDeep TechHardwareWaltham, US
Micah K Johnson(Executive Officer, Director)Janos Rohaly(Executive Officer)Edward Adelson(Director)Micah Kimo Johnson(Executive Officer, Director)William J. Yost(Executive Officer, Director)
Co-investorsAnzu PartnersScout VenturesScout Ventures
nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.
BiotechDeep TechMedical Devices
Luke Gilbert, PhDKeith Joung, MD, PhDDavid Liu, PhDAngelo Lombardo, PhDLuigi Naldini, MD, PhDJonathan Weissman, PhD
Co-investorsAtlas VentureNewpath PartnersARCH Venture PartnersDCVC (Data Collective)F-Prime Capital5AM Ventures+1 more
Protego provides chargeback management software that automates dispute processes and tracks chargebacks in real time to help merchants identify patterns in fraudulent activity and recover revenue.
CybersecurityEnterprise SoftwareSaaSBogotá, CO
Pablo Rojas(Founder)in
Co-investorsNovartis Venture FundY CombinatorForbionGlilot Capital PartnersYK Bioventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.